The 2016 revision of the World Health Organization classification of lymphoid neoplasms

• Published in: Blood Vol. 127; no. 20; pp. 2375 - 2390
• Main Authors: Swerdlow, Steven H., Campo, Elias, Pileri, Stefano A., Harris, Nancy Lee, Stein, Harald, Siebert, Reiner, Advani, Ranjana, Ghielmini, Michele, Salles, Gilles A., Zelenetz, Andrew D., Jaffe, Elaine S.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 19.05.2016; American Society of Hematology
• Subjects: Cancer; Genes, Neoplasm; Humans; Leukemia, Lymphoid - classification; Leukemia, Lymphoid - genetics; Leukemia, Lymphoid - pathology; Life Sciences; Lymphatic Diseases - classification; Lymphatic Diseases - genetics; Lymphatic Diseases - pathology; Lymphocytes - pathology; Lymphoma - classification; Lymphoma - genetics; Lymphoma - pathology; Oncogene Proteins, Fusion - genetics; Paraproteinemias - classification; Paraproteinemias - genetics; Paraproteinemias - pathology; Review Series; The Updated WHO Classification of Hematological Malignancies; World Health Organization; pathology; Laboratories; Berlin; diagnosis; classification; Switzerland; Consensus; Neoplasms; Medicine; Medical Oncology; genetics; Biomedical Research; Italy; France; Germany
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood-2016-01-643569

A revision of the nearly 8-year-old World Health Organization classification of the lymphoid neoplasms and the accompanying monograph is being published. It reflects a consensus among hematopathologists, geneticists, and clinicians regarding both updates to current entities as well as the addition of a limited number of new provisional entities. The revision clarifies the diagnosis and management of lesions at the very early stages of lymphomagenesis, refines the diagnostic criteria for some entities, details the expanding genetic/molecular landscape of numerous lymphoid neoplasms and their clinical correlates, and refers to investigations leading to more targeted therapeutic strategies. The major changes are reviewed with an emphasis on the most important advances in our understanding that impact our diagnostic approach, clinical expectations, and therapeutic strategies for the lymphoid neoplasms.